{"organizations": [], "uuid": "e4ddaa6d549de2e97defb76c0117410315f32ec2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/astrazeneca-cancer/astrazeneca-third-line-lung-cancer-combination-study-fails-idUSL8N1S1197", "country": "US", "domain_rank": 408, "title": "AstraZeneca third-line lung cancer combination study fails", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.893, "site_type": "news", "published": "2018-04-24T14:36:00.000+03:00", "replies_count": 0, "uuid": "e4ddaa6d549de2e97defb76c0117410315f32ec2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/astrazeneca-cancer/astrazeneca-third-line-lung-cancer-combination-study-fails-idUSL8N1S1197", "ord_in_thread": 0, "title": "AstraZeneca third-line lung cancer combination study fails", "locations": [], "entities": {"persons": [{"name": "louise heavens", "sentiment": "none"}, {"name": "imfinzi", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "imfinzi", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live longer.\nThe disappointing results from the so-called ARCTIC study, announced on Tuesday, are a fresh setback for the idea of using two immunotherapy drugs together. The Phase III ARCTIC study was testing a combination of Imfinzi and tremelimumab.\nA sub-study that was not powered for statistical significance did, however, find that Imfinzi monotherapy showed a clinically meaningful reduction in the risk of death compared to chemotherapy. (Reporting by Ben Hirschler, editing by Louise Heavens)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-24T14:36:00.000+03:00", "crawled": "2018-04-25T14:44:05.005+03:00", "highlightTitle": ""}